Acacia Pharma
Acacia Pharma is a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.
Key Products in the products portfolio are; BARHEMSYS® (intravenous amisulpride): approved in the US for the treatment and prophylaxis of postoperative nausea & vomiting (PONV) either alone or incombination with antiemetics of a different class (February 2020) with US launch planned in 2H 2020 and BYFAVO™ (remimazolam) for injection: approved in the US for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less (July 2020). BYFAVO is in-licensed from Cosmo Pharmaceuticals for the US market. US launch is planned in 2H 2020.
